Additionally, finerenone, a non-steroidal mineralocorticoid receptor antagonist, was evaluated in the FINEARTS-HF trial, which reported a reduction in the composite of cardiovascular mortality and heart failure hospitalization [41]. This evidence concerns the gene NR3C2 and heart failure.